A PHASE-II STUDY OF RECOMBINANT HUMAN ALPHA-INTERFERON IN ADVANCED HORMONE-REFRACTORY PROSTATE-CANCER

被引：0

作者：

VANHAELSTPISANI, CM ^{[1
]}

RICHARDSON, RL ^{[1
]}

SU, J ^{[1
]}

BUCKNER, JC ^{[1
]}

HAHN, RG ^{[1
]}

FRYTAK, S ^{[1
]}

KVOLS, LK ^{[1
]}

BURCH, PA ^{[1
]}

机构：

[1] MAYO CLIN & MAYO FDN,CTR CANC,STAT UNIT,ROCHESTER,MN 55905

来源：

CANCER | 1992年 / 70卷 / 09期

关键词：

D O I：

10.1002/1097-0142(19921101)70:9<2310::AID-CNCR2820700916>3.0.CO;2-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To determine the efficacy of recombinant human leukocyte alpha-interferon (IFL-RA) in advanced hormone-refractory prostate cancer, the authors treated 40 patients with IFL-RA administered intramuscularly at a dose of 10 X 10(6), U/m2 three times weekly. Toxicity was substantial and necessitated at least a 50% dose reduction in all but five patients during the first 1-2 months of therapy. No responses were observed in patients with bone metastases, but complete and partial regression of nodal disease were observed in two patients with extraosseous disease (overall response rate, 5%; 95% confidence interval, 0.64-17.75%). The authors conclude that IFL-RA cannot he recommended at this dose and schedule in patients with advanced prostate cancer, but additional study of its use in patients with nodal disease may be warranted.

引用

页码：2310 / 2312

页数：3

共 8 条

[1] INTERFERON-BETA TREATMENT OF METASTATIC PROSTATE-CANCER [J].

BULBUL, MA ;

HUBEN, RP ;

MURPHY, GP .

JOURNAL OF SURGICAL ONCOLOGY, 1986, 33 (04) :231-233

[2] TOXICITIES OF HUMAN RECOMBINANT INTERFERON-ALPHA2 IN PATIENTS WITH ADVANCED PROSTATE CARCINOMA [J].

CHANG, AYC ;

FISHER, HAG ;

SPIERS, ASD ;

BOROS, L .

JOURNAL OF INTERFERON RESEARCH, 1986, 6 (06) :713-715

[3] INTERFERONS - PRESENT AND FUTURE USE IN CANCER-THERAPY [J].

GOLOMB, HM .

JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (02) :123-125

[4]

Gutterman J, 1981, Tex Rep Biol Med, V41, P626

[5] DOXORUBICIN, MITOMYCIN-C, AND 5-FLUOROURACIL (DMF) IN THE TREATMENT OF METASTATIC HORMONAL REFRACTORY ADENOCARCINOMA OF THE PROSTATE, WITH A NOTE ON THE STAGING OF METASTATIC PROSTATE-CANCER [J].

LOGOTHETIS, CJ ;

SAMUELS, ML ;

VONESCHENBACH, AC ;

TRINDADE, A ;

OGDEN, S ;

GRANT, C ;

JOHNSON, DE .

JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (06) :368-379

[6] CLINICAL-RESULTS OF LEUKOCYTE INTERFERON-INDUCED TUMOR-REGRESSION IN RESISTANT HUMAN METASTATIC CANCER RESISTANT TO CHEMOTHERAPY AND OR RADIOTHERAPY-PULSE THERAPY SCHEDULE [J].

MEDENICA, R ;

SLACK, N .

CANCER DRUG DELIVERY, 1985, 2 (01) :53-76

[7] A TRIAL OF COMBINATION CHEMOTHERAPY FOLLOWED BY HORMONAL-THERAPY FOR PREVIOUSLY UNTREATED METASTATIC CARCINOMA OF THE PROSTATE [J].

SEIFTER, EJ ;

BUNN, PA ;

COHEN, MH ;

MAKUCH, RW ;

DUNNICK, NR ;

JAVADPOUR, N ;

BENSIMON, H ;

EDDY, JL ;

MINNA, JD ;

IHDE, DC .

JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (09) :1365-1373

[8]

SICA G, 1989, UROL RES, V17, P111

← 1 →